Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance study
Hideto Kameda(Toho University), Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Sadatomo Tasaka(Hirosaki University), Naoki Soeda(Asahi Kasei (Japan)), Katsuhisa Suzuki(Sanofi (Japan)), Hubert van Hoogstraten(Sanofi (United States)), Remco Diab(Sanofi (Switzerland)), Toshiya Takahashi(Tohoku University)
Cited by 4
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|413